[ Back to EurekAlert! ] Public release date: 25-Apr-2012
[ | E-mail Share Share ]

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital

Bacteria beware

Researchers have a natural sidekick that may resolve the antibiotic-resistant bacteria dilemma

BOSTON, MA—Antibiotic-resistant bacteria continue to be a global concern with devastating repercussions, such as increased healthcare costs, potential spread of infections across continents, and prolonged illness.

However, researchers at Brigham and Women's Hospital (BWH) could change the playing field of man versus bacteria. Charles Serhan, PhD, director of the BWH Experimental Therapeutics and Reperfusion Injury Center, has identified pathways of naturally occurring molecules in our bodies that can enhance antibiotic performance.

The study will be electronically published on April 25, 2012 in Nature.

Mice infected with Escherichia coli (E. coli) or Staphylococcus aureus (S. aureus) bacteria were given molecules called specialized pro-resolving mediators (SPMs) along with antibiotics. SPMs are naturally found in our bodies, and are responsible for mediating anti-inflammatory responses and resolve inflammation. An anti-inflammatory response is the body's attempt to protect itself from infectious agents and initiate the healing process.

The researchers found that specific types of SPM molecules, called resolvins and protectins, were key in the anti-inflammatory response to limit tissue damage by stimulating the body's white blood cells to contain, kill and clear the bacteria.

Administered with antibiotics, resolvins and protectins heightened immune response by commanding white blood cells to attack and engulf the bacteria, thereby quickly reducing the amount of bacteria in the blood and tissues.

RvD5—a type of resolvin—in particular was also helpful in regulating fever caused by E.coli, as well as counter-regulating genes responsible for mounting excess inflammation associated with infections; hence, limiting the collateral damage to the body while fighting infection.

Serhan and colleagues are the first to demonstrate RvD5, as well as its actions against bacterial invasion. The BWH team, collaborating with Fredrik Bäckhed, PhD of the Sahlgrenska Center for Cardiovascular and Metabolic Research in Sweden, found that germ-free animals produce high levels of resolvins.

When Nan Chiang, PhD, BWH Experimental Therapeutics and Reperfusion Injury Center, and lead study author, added these natural mediators together with antibiotics, less antibiotics were needed. This demonstrated for the first time that stimulating resolution programs can limit negative consequences of infection.

"How the body responds to inflammation has been the subject of Dr. Serhan's work for more than 20 years, and his new study is important for understanding that sequence of events," said Richard Okita, PhD, National Institute of General Medical Sciences, National Institutes of Health which funded the research. "One of the particularly exciting findings is that SPMs can enhance the effectiveness of antibiotics, potentially lowering the amount needed to treat infections and reducing the risk of bacteria developing resistance."

According to the researchers, another advantage of SPMs is that, unlike anti-inflammatory drugs (e.g. aspirin, steroids, ibuprofen), SPMs do not cripple the body's normal immune response.

"Anti-inflammatory agents are widely known to be immunosuppressive," said Serhan. "Now we have naturally occurring molecular pathways in our bodies that work like these agents and stimulate bacterial containment and resolution of infections, but do not come with the side effect of being immunosuppressive."

E. coli infections continue to be both a world- and nationwide concern. In the United States, E. coli infections account for approximately 270,000 cases per year. S. aureus is responsible for causing skin infections and a majority of hospital-acquired infections.

###

This research was 100 percent supported by the following grants from the National Institutes of Health and National Institute of General Medical Sciences: P01GM095467 and R01GM38765 (CNS).

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. BWH is the home of the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), www.brighamandwomens.org/research, BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 900 physician-investigators and renowned biomedical scientists and faculty supported by more than $537 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information about BWH, please visit www.brighamandwomens.org.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.